HEAD AND NECK SQUAMOUS CELL CARCINOMA
Clinical trials for HEAD AND NECK SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new HEAD AND NECK SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug QLS5316 enters first human tests for advanced cancers
Disease control Not yet recruitingThis early-phase study tests a new drug called QLS5316 in about 300 adults with advanced solid tumors (including colorectal, stomach, head and neck, and lung cancers) that have stopped responding to standard treatments. The main goals are to check the drug's safety, find the best…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 03:22 UTC
-
Experimental combo aims to boost immune attack on head and neck tumors
Disease control Not yet recruitingThis early-phase study tests a combination of two drugs—decitabine and nivolumab—in people with advanced head and neck cancer that has come back or spread. The goal is to see if decitabine can make cancer cells more visible to the immune system, helping nivolumab work better. Abo…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Kyunghee Burkitt, DO, PhD • Aim: Disease control
Last updated May 26, 2026 03:22 UTC
-
New drug cocktail aims to beat back head and neck cancer
Disease control Not yet recruitingThis study tests whether combining the immunotherapy drug camrelizumab with either an EGFR antibody or chemotherapy can help people with advanced head and neck cancer live longer and keep the cancer from coming back. About 246 adults aged 18-75 with stage III-IVb squamous cell ca…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: Yue He, MD • Aim: Disease control
Last updated May 26, 2026 03:17 UTC
-
New hope for hard-to-treat head and neck cancer: drug combo shows promise in early trial
Disease control Not yet recruitingThis study tests a new two-drug combination for people with recurrent head and neck cancer that has stopped responding to standard immunotherapy and chemotherapy. The drugs are given before surgery to shrink the tumor, followed by standard treatments and maintenance therapy. The …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated May 26, 2026 03:17 UTC
-
New drug combo aims to shrink head and neck tumors before surgery
Disease control Not yet recruitingThis study tests whether giving a drug called becotatug vedotin, alone or with immunotherapy (penpulimab or ivonescimab), before surgery can help shrink advanced head and neck cancers. About 120 adults aged 18-70 with resectable tumors will take part. The main goal is to see if t…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: West China Hospital • Aim: Disease control
Last updated May 26, 2026 03:17 UTC
-
New drug IDP-001 takes on advanced cancers in early trial
Disease control Not yet recruitingThis study tests a new drug called IDP-001 in people with advanced or spreading solid tumors, including certain lung, head and neck, and other cancers. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. About 132 adults who have t…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: InduPro, Inc. • Aim: Disease control
Last updated May 26, 2026 03:15 UTC
-
Triple-Drug attack before surgery shows promise against tough head & neck cancer
Disease control Not yet recruitingThis study tests whether giving three drugs together before surgery can better shrink advanced head and neck tumors. About 30 adults with stage III/IVA cancer will receive the combination for 6-12 weeks, then have surgery. Researchers will check how many patients have no cancer l…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Sir Run Run Shaw Hospital • Aim: Disease control
Last updated May 26, 2026 03:13 UTC
-
New shorter radiation course aims to cut side effects for head and neck cancer patients
Disease control Not yet recruitingThis study tests a shorter, more intense radiation schedule (hypofractionated radiotherapy) for 60 adults with intermediate-risk head and neck cancer who have had surgery. The goal is to see if this approach is safe and effective at controlling the cancer while reducing late side…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: NA • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated May 26, 2026 03:12 UTC
-
New hope for head and neck cancer patients who Can't take standard chemo
Disease control Not yet recruitingThis study tests two different treatments for people with advanced head and neck cancer who cannot receive the standard drug cisplatin. Participants will get radiation therapy along with either cetuximab (a targeted antibody) or a combination of two chemotherapy drugs, carboplati…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated May 26, 2026 03:12 UTC
-
New drug duo aims to shrink head and neck tumors before surgery
Disease control Not yet recruitingThis study tests whether adding two drugs (pucotenlimab and becotatug vedotin) to standard surgery can improve outcomes for people with advanced head and neck cancer that can be removed. About 80 participants will receive the drug combination or a placebo before and after surgery…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Lepu Biopharma Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 03:10 UTC
-
New drug cocktail shows promise against tough head and neck cancers
Disease control Not yet recruitingThis study tests a combination of three treatments—ficerafusp alfa, pembrolizumab, and targeted radiation—given before surgery for people with advanced head and neck cancer that is HPV-negative. About 45 participants will receive the drugs and radiation, then undergo standard sur…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
New combo therapy aims to stop head and neck cancer recurrence in intermediate-risk patients
Disease control Not yet recruitingThis study tests whether adding the drug benmelstobart to standard radiation and nimotuzumab can help prevent head and neck cancer from returning after surgery. About 386 adults with intermediate-risk features (like advanced tumor stage or close surgical margins) will be randomly…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University • Aim: Disease control
Last updated May 19, 2026 12:01 UTC
-
Radiation plus immunotherapy before surgery shows promise in head and neck cancer trial
Disease control Not yet recruitingThis study tests whether adding radiation to immunotherapy before surgery can improve outcomes for people with advanced head and neck cancer. About 36 participants will receive either the combination or immunotherapy alone before their tumor is removed. The goal is to see if the …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Chen Chunyan • Aim: Disease control
Last updated May 19, 2026 11:46 UTC
-
Virus and chemo combo takes on hard-to-treat head and neck cancer
Disease control Not yet recruitingThis study tests a treatment that combines a modified virus (H101) with a procedure called TACE (chemoembolization) for people with recurrent or metastatic head and neck cancer that hasn't responded to at least two prior treatments. The goal is to kill tumor cells and activate th…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: West China Hospital • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New imaging agent could help spot Hard-to-Find cancers
Diagnosis Not yet recruitingThis early study tests a new radioactive drug called NTH-2403 in about 16 people with advanced colorectal, head and neck, lung, or triple-negative breast cancers. The drug is designed to attach to a protein found on certain cancer cells and light them up on scans. The main goal i…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Radiopharm Theranostics, Ltd • Aim: Diagnosis
Last updated May 26, 2026 03:20 UTC
-
Blood test could spot hidden HPV cancers before symptoms start
Diagnosis Not yet recruitingThis study aims to see if a simple blood test can find HPV-related throat and anal cancers early in men aged 50 and older. Participants will provide blood samples to check for signs of the virus and tumor DNA. If successful, this could lead to a national screening program to catc…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: NA • Sponsor: UNICANCER • Aim: Diagnosis
Last updated May 18, 2026 12:00 UTC
-
Glow-in-the-dark dye could help surgeons spot cancer during operations
Diagnosis Not yet recruitingThis early-phase trial tests a fluorescent dye called ABY-029 that makes cancer cells glow during surgery. The goal is to find the right dose so surgeons can better see and remove head and neck tumors. About 24 adults with operable head and neck cancer will receive a tiny amount …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Dartmouth-Hitchcock Medical Center • Aim: Diagnosis
Last updated May 06, 2026 16:03 UTC
-
Could less radiation be better for HPV throat cancer? new trial aims to find out
Symptom relief Not yet recruitingThis study tests whether lowering radiation doses to certain areas can reduce side effects for people with HPV-related throat cancer, which typically has good outcomes. About 132 participants will receive either reduced radiation to low-risk lymph nodes, a lower dose to the tumor…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: University of Maryland, Baltimore • Aim: Symptom relief
Last updated May 20, 2026 11:53 UTC